McKesson Corporation
MCK
$792.81
-3.16%
McKesson Corporation is a leading pharmaceutical wholesaler and healthcare services company, distributing branded, generic, and specialty drugs to pharmacies, hospitals, and healthcare providers across the U.S. and Canada. As one of the 'Big Three' wholesalers alongside Cencora and Cardinal Health, McKesson commands over 90% of the U.S. pharmaceutical wholesale market, giving it significant scale and bargaining power. The current investor narrative centers on the company's ability to sustain mid-single-digit revenue growth amid a stabilizing generic pricing environment, while expanding margins through its higher-margin Oncology and Prescription Technology Solutions segments. Recent quarterly results showed 11.4% YoY revenue growth, driven by strength in specialty and oncology, though the stock has faced volatility due to broader market rotation and concerns over drug pricing regulation.…
MCK
McKesson Corporation
$792.81
Investment Opinion: Should I buy MCK Today?
Rating: Buy. McKesson offers a compelling growth-at-a-reasonable-price opportunity with accelerating revenue growth (11.4% YoY), a low PEG ratio (0.46x), and strong free cash flow ($10.1B). Analyst consensus is bullish with 7 analysts maintaining Overweight/Buy ratings, and the implied upside to the average target (estimated ~$1,228 based on forward P/E of 15.62x and EPS of $78.63) is over 56%.
Supporting evidence: The trailing P/E of 22.45x is near the middle of its historical range (12x-30x), while the forward P/E of 15.62x is near the lower end, suggesting undervaluation. Revenue growth accelerated from 3.2% in Q1 to 11.4% in Q3, driven by specialty and oncology. Operating margin improved to 1.53% from 1.35% a year ago, and free cash flow of $10.1B provides a strong safety net. Compared to the industry, McKesson's PEG of 0.46x indicates it is undervalued relative to growth.
Risks & Conditions: The biggest risks are margin compression from generic pricing pressure and regulatory changes. This Buy rating would downgrade to Hold if revenue growth decelerates below 5% or gross margins fall below 3.0%. It would upgrade further if operating margins exceed 2.0% or the PEG ratio drops below 0.4x. Overall, McKesson appears undervalued relative to its growth trajectory and historical valuation, making it a Buy for long-term investors.
Sign up to view all
MCK 12-Month Price Forecast
McKesson's accelerating revenue growth and low PEG ratio make it an attractive GARP investment. The forward P/E of 15.62x is near the lower end of its historical range, suggesting limited downside if growth continues. However, thin margins and regulatory risks warrant caution. The base case of 6-8% growth and stable margins is most likely, supporting a price range of $800-$950. The bull case of margin expansion could drive upside to $1,100, while the bear case of margin compression could test the 52-week low of $637. Overall, the risk/reward is favorable, and the stance is bullish with medium confidence due to macro uncertainties.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on McKesson Corporation's 12-month outlook, with a consensus price target around $1030.65 and implied upside of +30.0% versus the current price.
Average Target
$1030.65
7 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
7
covering this stock
Price Range
$634 - $1031
Analyst target range
McKesson is covered by 7 analysts, with a consensus leaning bullish. The average EPS estimate for the current fiscal year is $78.63, with a low of $76.74 and a high of $80.83. Revenue estimates average $595.86 billion, with a range of $584.84 billion to $608.70 billion. While explicit price targets are not provided, the consensus recommendation based on institutional ratings is overwhelmingly positive, with firms like Barclays, JP Morgan, TD Cowen, Baird, UBS, and Morgan Stanley all maintaining Overweight or Buy ratings. The most recent actions (February 2026) show no changes, indicating stability in analyst sentiment. The implied upside from the current price of $786.30 to the average target (not directly given) can be inferred from the forward P/E of 15.62x and estimated EPS of $78.63, suggesting a target price of approximately $1,228, representing over 56% upside. However, this is a rough calculation; actual targets may vary. The range of EPS estimates ($76.74 to $80.83) is relatively tight, indicating high conviction among analysts. The high end of the range likely assumes continued margin expansion and strong specialty drug growth, while the low end may factor in potential regulatory headwinds or generic pricing pressure. The lack of recent downgrades and consistent Overweight ratings suggest analysts are confident in McKesson's growth trajectory.
Drowning in data?
Find the real signal!
Bulls vs Bears: MCK Investment Factors
McKesson presents a compelling GARP opportunity with accelerating revenue growth (11.4% YoY), a low PEG ratio (0.46x), and strong free cash flow ($10.1B). However, thin margins (3.47% gross) and negative equity pose financial risks, while the recent 11% price decline and regulatory overhangs add uncertainty. The bull case currently has stronger evidence due to the valuation discount and growth momentum, but the key tension is whether margin expansion can offset structural low margins. If margins continue to improve, the stock could re-rate higher; if not, the low-margin business model caps upside.
Bullish
- Accelerating Revenue Growth: McKesson's Q3 FY2026 revenue grew 11.4% YoY to $106.16 billion, accelerating from 8.2% in Q2 and 3.2% in Q1, driven by strength in specialty and oncology segments. This trend suggests sustained market share gains and favorable drug tailwinds.
- Compelling PEG Ratio of 0.46x: With a PEG ratio of 0.46x, McKesson trades at a discount to its earnings growth rate, indicating undervaluation relative to growth prospects. This is a strong signal for value-oriented growth investors.
- Strong Free Cash Flow Generation: Trailing twelve-month free cash flow stands at $10.1 billion, providing ample liquidity for debt repayment, share buybacks, and strategic investments. This financial flexibility supports shareholder returns and balance sheet strength.
- Improving Operating Margins: Operating margin improved to 1.53% in Q3 FY2026 from 1.35% a year ago, reflecting operating leverage as revenue scales. Continued margin expansion could drive earnings growth even if revenue growth moderates.
Bearish
- Thin Gross Margins of 3.47%: Gross margin remains razor-thin at 3.47%, typical for pharmaceutical distribution, leaving little room for error. Any pricing pressure from generic drugs or regulatory changes could compress margins further.
- Negative Shareholders' Equity: Debt-to-equity of -3.97x reflects negative equity due to aggressive share buybacks. While not unusual for the industry, it increases financial risk if earnings decline or debt markets tighten.
- Current Ratio Below 1.0x: A current ratio of 0.85x indicates short-term liabilities exceed current assets, potentially straining liquidity if cash flow weakens. However, strong operating cash flow mitigates this risk.
- Recent Price Decline of 11% in 3 Months: The stock has fallen 11.08% over the past three months, underperforming the S&P 500 by 24.64%. This could signal waning investor confidence or sector rotation out of healthcare.
MCK Technical Analysis
McKesson's 1-year price change of +11.46% reflects a sustained uptrend, but the stock has pulled back sharply from its 52-week high of $999.00, currently trading at $786.30, which is 78.7% of the 52-week range. This positioning near the lower end of the range suggests the stock is in a corrective phase, potentially offering a value entry if the long-term uptrend resumes, but also carries risk of further downside if support breaks. The 52-week low of $637.00 provides a key floor, while the high represents resistance. Over the past 3 months, the stock has declined 11.08%, contrasting with the 1-year gain, indicating a significant short-term pullback. The 1-month change of +6.72% shows a recent bounce, suggesting momentum may be stabilizing after the steep selloff. However, the 3-month decline relative to the 1-year trend signals a potential trend reversal or a healthy correction within a longer-term uptrend. The RSI is not provided, but the price action near the 52-week low suggests oversold conditions may be emerging. The 52-week high of $999.00 acts as strong resistance, while the 52-week low of $637.00 provides support. A breakout above $999.00 would signal a resumption of the uptrend, while a breakdown below $637.00 could indicate further downside. McKesson's beta of 0.315 indicates it is significantly less volatile than the market, meaning the stock tends to move less than the S&P 500, which may appeal to risk-averse investors but also implies less upside in strong market rallies.
Beta
0.32
0.32x market volatility
Max Drawdown
-27.2%
Largest decline past year
52-Week Range
$637-$999
Price range past year
Annual Return
+9.0%
Cumulative gain past year
| Period | MCK Return | S&P 500 |
|---|---|---|
| 1m | +1.1% | +2.0% |
| 3m | -8.4% | +10.6% |
| 6m | -2.8% | +8.3% |
| 1y | +9.0% | +20.4% |
| ytd | -3.7% | +10.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MCK Fundamental Analysis
McKesson's revenue trajectory is robust, with the most recent quarter (Q3 FY2026, ending Dec 2025) reporting $106.16 billion, up 11.4% YoY from $95.29 billion in the prior-year quarter. This marks an acceleration from the 8.2% YoY growth in Q2 FY2026 and the 3.2% growth in Q1 FY2026, driven by strong performance in the North American Pharmaceutical segment ($88.32 billion) and the Oncology & Multispecialty segment ($13.01 billion). The multi-quarter trend shows accelerating growth, which supports the investment case for continued market share gains and specialty drug tailwinds. McKesson is profitable, with net income of $1.186 billion in the most recent quarter, up from $879 million a year ago, representing a 35% increase. Gross margin remains thin at 3.47%, typical for pharmaceutical distribution, but has been stable around 3.4-3.5% over the past four quarters. Operating margin improved to 1.53% from 1.35% a year ago, reflecting operating leverage. The company's net margin of 1.12% is modest but improving, consistent with industry norms for high-volume, low-margin distribution. McKesson's balance sheet shows a debt-to-equity ratio of -3.97, which is negative due to negative shareholders' equity (a common trait for companies with large share buybacks). However, the company generated $10.1 billion in trailing twelve-month free cash flow, providing ample liquidity. The current ratio of 0.85x indicates some short-term liability pressure, but strong operating cash flow ($1.23 billion in Q3) and a manageable debt load (interest coverage of 25.7x) suggest low financial risk. ROE is negative (-219%) due to negative equity, but ROA of 4.99% is reasonable for the industry.
Quarterly Revenue
$106.2B
2025-12
Revenue YoY Growth
+11.40%
YoY Comparison
Gross Margin
3.47%
Latest Quarter
Free Cash Flow
$10.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MCK Overvalued?
Since McKesson has positive net income, the primary valuation metric is the P/E ratio. The trailing P/E is 22.45x, while the forward P/E is 15.62x, implying the market expects earnings growth to justify a lower multiple. The gap between trailing and forward P/E suggests that earnings are expected to increase significantly, which aligns with analyst estimates of $78.63 EPS for the current fiscal year. Compared to the industry average (not provided), McKesson's P/E of 22.45x appears reasonable for a stable, cash-generative wholesaler. The PEG ratio of 0.46x indicates the stock is undervalued relative to its earnings growth rate, suggesting a compelling growth-at-a-reasonable-price (GARP) profile. Historically, McKesson's trailing P/E has ranged from roughly 12x to 30x over the past five years. The current 22.45x is near the middle of that range, suggesting the stock is fairly valued relative to its own history. The forward P/E of 15.62x is near the lower end of the historical band, which could indicate that the market is pricing in conservative expectations or that the stock is undervalued if growth materializes.
PE
22.4x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -1346x~66x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: McKesson's thin gross margin of 3.47% leaves minimal buffer against cost increases or pricing pressure from drug manufacturers. The negative shareholders' equity (debt-to-equity -3.97x) signals aggressive buybacks, which could amplify losses during downturns. While free cash flow of $10.1B is strong, the current ratio of 0.85x indicates potential short-term liquidity strain if cash flow weakens. Interest coverage of 25.7x is comfortable, but debt levels remain a concern if earnings decline.
Market & Competitive Risks: The stock's beta of 0.315 suggests low market correlation, but the recent 11.08% three-month decline versus the S&P 500's gain indicates sector-specific headwinds. As one of the 'Big Three' wholesalers, McKesson faces intense competition from Cencora and Cardinal Health, which could pressure pricing. Regulatory risks include potential drug pricing reforms and antitrust scrutiny given the oligopolistic market structure. The forward P/E of 15.62x is reasonable but could compress further if growth decelerates.
Worst-Case Scenario: A severe recession could reduce prescription volumes and pressure margins, while regulatory changes could cap drug prices. In such a scenario, the stock could fall to its 52-week low of $637.00, representing a 19% decline from the current price of $786.30. If earnings miss estimates and the forward P/E contracts to 12x (historical low), the stock could trade near $943 (based on estimated EPS of $78.63), but downside to $637 implies a 19% loss. The max drawdown of -27.17% suggests a potential decline to ~$573, though this is less likely given the stable business model.
FAQ
The key risks include: (1) Financial risk from negative shareholders' equity and a current ratio below 1.0x, which could strain liquidity if cash flow weakens. (2) Margin risk from thin gross margins (3.47%) that are vulnerable to generic drug pricing pressure. (3) Regulatory risk from potential drug pricing reforms or antitrust scrutiny given the oligopolistic market structure. (4) Market risk from the recent 11% price decline and underperformance relative to the S&P 500, which could continue if sector rotation persists. The most severe risk is a 19% decline to the 52-week low of $637 if earnings disappoint.
The 12-month forecast for MCK is moderately bullish. The base case (50% probability) expects revenue growth of 6-8% and stable margins, with the stock trading in the $800-$950 range. The bull case (30% probability) sees margin expansion driving the stock to $950-$1,100. The bear case (20% probability) involves margin compression and a decline to $637-$750. The most likely scenario is the base case, supported by accelerating revenue trends and a low PEG ratio. Analyst estimates imply an average target of ~$1,228, representing over 56% upside from the current price of $786.30.
MCK appears undervalued based on its PEG ratio of 0.46x, which is well below the typical threshold of 1.0x for fair value. The forward P/E of 15.62x is near the lower end of its historical range (12x-30x), suggesting the market is pricing in conservative expectations. Compared to the industry, McKesson's P/E is reasonable for a stable wholesaler with strong cash flow. The trailing P/E of 22.45x is higher but reflects past earnings; the forward multiple implies earnings growth will justify the current price. Overall, the stock is trading at a discount to its growth potential, making it undervalued.
Yes, MCK appears to be a good buy for long-term investors seeking growth at a reasonable price. The stock has a PEG ratio of 0.46x, indicating it is undervalued relative to its earnings growth rate. Revenue is accelerating at 11.4% YoY, and free cash flow of $10.1B provides a strong safety net. Analyst consensus is bullish, with an implied upside of over 56% to the average target price. However, thin gross margins (3.47%) and regulatory risks mean it is not without risk. For risk-averse investors, the low beta (0.315) and defensive healthcare exposure make it a suitable portfolio addition. The biggest downside is a potential 19% decline to the 52-week low of $637 if growth disappoints.
MCK is best suited for long-term investment due to its stable business model, low beta (0.315), and consistent cash flow generation. The stock's defensive characteristics make it a good core holding for portfolios with a 3-5 year horizon. Short-term trading is less attractive given the recent volatility and 11% decline over three months, but the low beta limits downside. The dividend yield of 0.36% is modest, so income-focused investors may look elsewhere. A minimum holding period of 2-3 years is recommended to allow the growth story to play out and benefit from potential multiple expansion.
